Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> CLSA Raises TP of JINGFANG PHARMACEUTICAL (02595.HK) to HKD61.9, Rating 'Outperform'
Recommend 1 Positive 3 Negative 1 |
||||
|
||||
|
CLSA released a research report stating that JINGFANG PHARMACEUTICAL-B (02595.HK) saw a 24.4% year-on-year increase in revenue and a net loss of RMB1.795 billion last year, both exceeding market expectations. G12D GFH375 has entered the pancreatic cancer registration trial phase, and pan-RAS GFH276 is expected to be a long-term growth driver for JINGFANG PHARMACEUTICAL. Positive safety signals have been observed in the Phase I dose-escalation trial of GFH276. The firm noted that it has raised the company's earnings forecast for this year and next by 4% and 5.3%, respectively, and increased its target price from HKD60.8 to HKD61.9, maintaining its rating at 'Outperform'. (ca/da) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
URL: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
